Outcomes
Cross-source consensus on Outcomes from 1 sources and 5 claims.
1 sources · 5 claims
Evidence quality
Other
Highlighted claims
- The primary outcome is a one-year composite endpoint after ICU discharge or randomisation. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- A participant meets the primary outcome if any composite component occurs during follow-up. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- Secondary endpoints are assessed at every visit and at one year plus six weeks after randomisation. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- Selected outcomes, including unscheduled hospitalisations for heart failure, are blindly adjudicated by an independent adjudication committee. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)
- Most secondary analyses are exploratory or hypothesis-generating and will emphasize effect sizes and 95% confidence intervals. — Dapagliflozin for cardiorenal protection after intensive care unit discharge: a protocol for a randomised controlled trial evaluating dapagliflozin at ICU discharge for cardiorenal protection (DAPA-ICU)